Danone: A strong first half; Consistently delivering quality results
Danone (OTC:DANOY) reported strong H1 2025 results with sales reaching �13,737 million, up +4.2% like-for-like, driven by volume/mix growth of +2.6% and price increase of +1.7%. The company's recurring operating margin expanded by 49 basis points to 13.2%, while recurring EPS grew +5.8% to �1.91.
Key highlights include strong performance in Specialized Nutrition (+7.0% LFL) and significant growth in China, North Asia & Oceania region (+11.3% LFL). The company completed strategic acquisitions including Kate Farms, the #1 doctor-recommended plant-based brand in the U.S., and The Akkermansia Company in the biotics sector.
Danone confirmed its 2025 guidance, projecting like-for-like sales growth between +3% and +5%, with recurring operating income growing faster than sales.
Danone (OTC:DANOY) ha riportato risultati solidi nel primo semestre 2025 con vendite pari a 13.737 milioni di �, in crescita del +4,2% a tassi di cambio costanti, trainate da una crescita del volume/mix del +2,6% e un aumento dei prezzi del +1,7%. Il margine operativo ricorrente si è ampliato di 49 punti base raggiungendo il 13,2%, mentre l'utile per azione ricorrente è cresciuto del +5,8% a �1,91.
Tra i punti salienti si evidenzia la forte performance della Nutrition Specializzata (+7,0% a tassi costanti) e una crescita significativa nelle regioni Cina, Nord Asia e Oceania (+11,3% a tassi costanti). L'azienda ha completato acquisizioni strategiche, tra cui Kate Farms, il marchio plant-based più raccomandato dai medici negli Stati Uniti, e The Akkermansia Company nel settore dei biotici.
Danone ha confermato le previsioni per il 2025, prevedendo una crescita delle vendite a tassi costanti compresa tra +3% e +5%, con un aumento del reddito operativo ricorrente più rapido rispetto alle vendite.
Danone (OTC:DANOY) reportó sólidos resultados en el primer semestre de 2025 con ventas que alcanzaron los 13.737 millones de �, un aumento del +4,2% a tipo de cambio constante, impulsado por un crecimiento en volumen/mezcla del +2,6% y un incremento de precios del +1,7%. El margen operativo recurrente se amplió en 49 puntos básicos hasta el 13,2%, mientras que el BPA recurrente creció un +5,8% hasta �1,91.
Los aspectos destacados incluyen un fuerte desempeño en Nutrición Especializada (+7,0% a tipo de cambio constante) y un crecimiento significativo en las regiones de China, Norte de Asia y Oceanía (+11,3% a tipo de cambio constante). La compañía completó adquisiciones estratégicas, entre ellas Kate Farms, la marca basada en plantas número uno recomendada por médicos en EE.UU., y The Akkermansia Company en el sector de bióticos.
Danone confirmó sus previsiones para 2025, proyectando un crecimiento de ventas a tipo de cambio constante entre +3% y +5%, con un aumento del ingreso operativo recurrente superior al crecimiento de las ventas.
다논 (OTC:DANOY)은 2025� 상반기에 매출� 137� 3,700� 유로� 달하� 전년 동기 대� +4.2%(환율 변� 제외) 성장했다� 발표했습니다. 이는 판매� � 믹스 증가 +2.6%, 가� 인상 +1.7%� 힘입은 결과입니�. 회사� 반복 영업이익률은 49 베이시스 포인� 상승하여 13.2%� 기록했고, 반복 주당순이�(EPS)은 +5.8% 증가� �1.91� 기록했습니다.
주요 성과로는 전문 영양 부�(+7.0% 환율 조정 기준)� 강력� 성장� 중국, 북아시아 � 오세아니� 지역에서의 � 폭의 성장(+11.3% 환율 조정 기준)� 포함됩니�. 회사� 미국에서 의사들이 가� 추천하는 식물� 브랜드인 Kate Farms와 바이오틱� 분야� The Akkermansia Company� 전략적으� 인수 완료했습니다.
다논은 2025� 가이던스를 유지하며, 환율 변� 제외 매출 성장률을 +3%에서 +5% 사이� 예상하고 있으�, 반복 영업이익은 매출보다 � 빠르� 증가� 것으� 전망했습니다.
Danone (OTC:DANOY) a publié de solides résultats pour le premier semestre 2025 avec un chiffre d'affaires atteignant 13 737 millions d'euros, en hausse de +4,2% à périmètre et taux de change constants, porté par une croissance du volume/mix de +2,6% et une augmentation des prix de +1,7%. La marge opérationnelle récurrente s'est accrue de 49 points de base pour atteindre 13,2%, tandis que le BPA récurrent a progressé de +5,8% pour s'établir à 1,91 �.
Les points clés incluent une forte performance en Nutrition Spécialisée (+7,0% à périmètre constant) et une croissance significative dans la région Chine, Asie du Nord & Océanie (+11,3% à périmètre constant). L'entreprise a finalisé des acquisitions stratégiques, notamment Kate Farms, la marque végétale la plus recommandée par les médecins aux États-Unis, et The Akkermansia Company dans le secteur des biotiques.
Danone a confirmé ses objectifs pour 2025, prévoyant une croissance du chiffre d'affaires à périmètre constant comprise entre +3% et +5%, avec un résultat opérationnel récurrent croissant plus rapidement que les ventes.
Danone (OTC:DANOY) meldete starke Ergebnisse für das erste Halbjahr 2025 mit einem Umsatz von 13.737 Millionen �, was einem Wachstum von +4,2% auf vergleichbarer Basis entspricht, getragen durch ein Volumen-/Mixwachstum von +2,6% und eine Preiserhöhung von +1,7%. Die wiederkehrende operative Marge stieg um 49 Basispunkte auf 13,2%, während das wiederkehrende Ergebnis je Aktie um +5,8% auf �1,91 zunahm.
Zu den Highlights zählen die starke Entwicklung im Bereich Spezialisierte Ernährung (+7,0% auf vergleichbarer Basis) sowie ein deutliches Wachstum in der Region China, Nordasien & Ozeanien (+11,3% auf vergleichbarer Basis). Das Unternehmen schloss strategische Übernahmen ab, darunter Kate Farms, die führende pflanzenbasierte Marke, die von Ärzten in den USA empfohlen wird, und The Akkermansia Company im Biotik-Sektor.
Danone bestätigte seine Prognose für 2025 und erwartet ein Umsatzwachstum auf vergleichbarer Basis zwischen +3% und +5%, wobei das wiederkehrende operative Ergebnis schneller als der Umsatz wachsen soll.
- Like-for-like sales growth of +4.2% with strong volume/mix contribution of +2.6%
- Recurring operating margin improved by 49 bps to 13.2%
- Recurring EPS increased by +5.8% to �1.91
- Strong free cash flow generation of �1.2 billion
- Strategic acquisitions of Kate Farms and The Akkermansia Company strengthening portfolio
- Specialized Nutrition segment showed robust growth of +7.0% LFL
- China, North Asia & Oceania region delivered exceptional growth of +11.3% LFL
- Reported sales decreased by -0.1% due to negative currency impact (-2.9%)
- Waters segment showed weak performance with only +1.6% LFL growth
- Net debt increased to �9.1 billion from �8.6 billion in December 2024
- Non-recurring operating expenses of -�238 million including impairment charges
- Reported EPS declined -14.8% to �1.61
2025 Half-Year Results
Press release � Paris, July 30, 2025 at 7:30am CEST
A strong first half
Consistently delivering quality results
|
Half-Year 2025 Key Figures |
in millions of euros unless stated otherwise | H1 2024 | H1 2025 | Reported change | Like-for-like change (LFL) |
Sales | 13,757 | 13,737 | - | + |
Recurring operating income | 1,746 | 1,811 | + | |
Recurring operating margin | +49 bps | |||
Non-recurring operating income and expenses | 69 | (238) | (307) | |
Operating income | 1,814 | 1,573 | - | |
Operating margin | -174 bps | |||
Recurring net income � Group share | 1,162 | 1,231 | + | |
Non-recurring net income � Group share | 57 | (191) | (248) | |
Net income � Group share | 1,219 | 1,040 | - | |
Recurring diluted EPS (�) | 1.80 | 1.91 | + | |
EPS (�) | 1.89 | 1.61 | - | |
Cash flow from operating activities | 1,504 | 1,519 | + | |
Free cash flow | 1,248 | 1,172 | - |
1
Antoine de Saint-Affrique: CEO statement
We started chapter two of the Renew Danone strategy with a strong performance, demonstrating consistency in driving quality growth and reflecting the strength and resilience of our health-focused portfolio: sales for the first half increased by +
In a volatile and uncertain environment, we are consistently doubling down on our fundamentals, further fueling our winning platforms such as high protein, medical nutrition, Alpro and Aptamil, while moving forward with this next chapter of our strategy. We started actively complementing our portfolio, further investing in medical nutrition, acquiring Kate Farms in the US, and in next-generation biotics through The Akkermansia Company.
We remain focused on the consistent execution of our consumer-centric and science-based strategy and the delivery of our mid-term guidance.
I. HALF-YEAR RESULTS
Second quarter and half-year sales
In Q2 2025, sales stood at
In H1 2025, sales stood at
Sales by operating segment
� million except % | Q2 2024 | Q2 2025 | Reported change | LFL sales growth | Volume/mix growth | H1 2024 | H1 2025 | Reported change | LFL sales growth | Volume/mix growth | ||||||||||
BY GEOGRAPHICAL ZONE | ||||||||||||||||||||
Europe | 2,447 | 2,505 | + | + | + | 4,783 | 4,894 | + | + | + | ||||||||||
North America | 1,595 | 1,546 | - | + | + | 3,331 | 3,179 | - | + | + | ||||||||||
China, North Asia & Oceania | 1,001 | 1,080 | + | + | + | 1,841 | 2,017 | + | + | + | ||||||||||
Latin America | 810 | 714 | - | + | - | 1,556 | 1,411 | - | + | - | ||||||||||
Asia, Middle East & Africa | 1,084 | 1,067 | - | + | + | 2,246 | 2,236 | - | + | + | ||||||||||
BY CATEGORY | ||||||||||||||||||||
EDP | 3,298 | 3,261 | - | + | + | 6,785 | 6,632 | - | + | + | ||||||||||
Specialized Nutrition | 2,213 | 2,307 | + | + | + | 4,414 | 4,606 | + | + | + | ||||||||||
Waters | 1,426 | 1,345 | - | - | - | 2,557 | 2,500 | - | + | + | ||||||||||
TOTAL | 6,938 | 6,913 | - | + | + | 13,757 | 13,737 | - | + | + |
In Q2 2025, Europe sales were up +
In North America, sales were up +
China, North Asia & Oceania delivered another quarter of broad-based strong performance, with sales up +
In Latin America, sales were up +
In Asia, Middle East & Africa, sales increased by +
Sales by geography by category
Q2 2025 | Europe | North America | China, North Asia & Oceania | AMEA & Latin America | Total | |||||
Sales (₷) | LFL sales growth (%) | Sales (₷) | LFL sales growth (%) | Sales (₷) | LFL sales growth (%) | Sales (₷) | LFL sales growth (%) | Sales (₷) | LFL sales growth (%) | |
EDP | 1,102 | + | 1,375 | + | 107 | + | 677 | + | 3,261 | + |
Specialized Nutrition | 811 | + | 92 | + | 704 | + | 700 | + | 2,307 | + |
Waters | 591 | + | 79 | - | 269 | + | 405 | - | 1,345 | - |
Total Company | 2,505 | + | 1,546 | + | 1,080 | + | 1,782 | + | 6,913 | + |
H1 2025 | Europe | North America | China, North Asia & Oceania | AMEA & Latin America | Total | |||||
Sales (₷) | LFL sales growth (%) | Sales (₷) | LFL sales growth (%) | Sales (₷) | LFL sales growth (%) | Sales (₷) | LFL sales growth (%) | Sales (₷) | LFL sales growth (%) | |
EDP | 2,205 | + | 2,834 | + | 202 | + | 1,392 | + | 6,632 | + |
Specialized Nutrition | 1,610 | + | 189 | + | 1,370 | + | 1,437 | + | 4,606 | + |
Waters | 1,079 | + | 157 | + | 445 | + | 819 | - | 2,500 | + |
Total Company | 4,894 | + | 3,179 | + | 2,017 | + | 3,647 | + | 13,737 | + |
Recurring Operating Margin
Recurring operating income (₷) and margin (%) | H1 2024 | H1 2025 | Reported change | ||||||
₷ | Margin (%) | ₷ | Margin (%) | ||||||
BY GEOGRAPHICAL ZONE | |||||||||
Europe | 550 | 556 | -14 bps | ||||||
North America | 355 | 349 | +33 bps | ||||||
China, North Asia & Oceania | 563 | 620 | +12 bps | ||||||
Latin America | 35 | 61 | +206 bps | ||||||
Asia, Middle East & Africa | 243 | 226 | -72 bps | ||||||
BY CATEGORY | |||||||||
EDP | 512 | 521 | +31 bps | ||||||
Specialized Nutrition | 901 | 1,003 | +136 bps | ||||||
Waters | 333 | 287 | -152 bps | ||||||
Total | 1,746 | 1,811 | +49 bps |
ٲԴDzԱ’s recurring operating income reached
Net income and Earnings per share
H1 2024 | H1 2025 | |||||||||
in millions of euros unless stated otherwise | Recurring | Non-recurring | Total | Recurring | Non-recurring | Total | ||||
Operating income | 1,746 | 69 | 1,814 | 1,811 | (238) | 1,573 | ||||
Cost of net financial debt | (96) | (96) | (90) | (90) | ||||||
Other financial income and expense | (55) | (9) | (64) | (48) | (47) | (95) | ||||
Income before tax | 1,595 | 59 | 1,654 | 1,674 | (285) | 1,388 | ||||
Income tax | (429) | 25 | (404) | (458) | 84 | (373) | ||||
Effective tax rate | ||||||||||
Net income from fully consolidated companies | 1,166 | 85 | 1,250 | 1,216 | (201) | 1,015 | ||||
Share of profit (loss) of equity-accounted companies | 40 | (32) | 8 | 71 | (11) | 59 | ||||
Net income | 1,206 | 52 | 1,259 | 1,286 | (213) | 1,074 | ||||
� Group share | 1,162 | 57 | 1,219 | 1,231 | (191) | 1,040 | ||||
� Non-controlling interests | 44 | (5) | 39 | 55 | (22) | 34 | ||||
Diluted EPS (�) | 1.80 | 1.89 | 1.91 | 1.61 |
Recurring EPS increased by +
Non-recurring operating income and expense reached -
Cash flow and Debt
Free cash flow reached
As of June 30, 2025, ٲԴDzԱ’s net debt stood at
II. 2025 GUIDANCE
2025 guidance is confirmed, in line with the mid-term ambition: like-for-like sales growth expected between +
III. RECENT MAJOR DEVELOPMENTS
- April 1, 2025: Danone successfully issued an
�800 million bond with an 8-year maturity and a3.438% coupon. The settlement took place on April 7, 2025, and the bonds are listed on Euronext Paris. The bond issue was widely subscribed by a diversified investor base, confirming the high confidence in ٲԴDzԱ’s business model and credit profile. - April 24, 2025: At ٲԴDzԱ’s 2025 Annual General Meeting, shareholders approved all resolutions submitted for its approval by the Board of Directors, including the distribution of a dividend of
�2.15 per share in cash, up +2.4% compared to last year, and the proposed renewals of terms of office of Antoine de Saint-Affrique, Chief Executive Officer, as well as independent Directors Patrice Louvet, Géraldine Picaud and Susan Roberts. - May 12, 2025: Danone announced that it has entered into a definitive agreement to acquire a majority stake in Kate Farms, a fast-growing U.S. business and the #1 doctor-recommended plant-based brand in the U.S., offering a wide array of organic, plant-based nutrition products for both medical and everyday needs. The acquisition was successfully completed on July 1, 2025.
- May 29, 2025: Danone announced that Shane Grant, Group Deputy CEO, CEO Americas and EVP Dairy, Plant-Based and Global Sales, and a member of ٲԴDzԱ’s Executive Committee, had decided to pursue a new opportunity outside of the company. His move was effective on June 13, 2025. For now, Véronique Penchienati-Bosetta, Group Deputy CEO, has taken Shane’s scope, in addition to her current responsibilities.
- June 25, 2025: Danone announced the acquisition of The Akkermansia Company (TAC), a Belgian company with nearly 20 years of history and science, specializing in biotics. Expanding deeper into gut health is a key facet of ٲԴDzԱ’s Renew strategy, as it doubles down on science and innovation, and as consumer interest in healthy products continues to rise.
IV. IFRS STANDARDS AND ALTERNATIVE PERFORMANCE MEASURES NOT DEFINED BY IFRS
IAS 29: impact on reported data
Danone has applied IAS 29 in hyperinflationary countries, as defined in IFRS. Adoption of IAS 29 in hyperinflationary countries requires their non-monetary assets and liabilities and their income statement to be restated to reflect the changes in the general purchasing power of their functional currency, leading to a gain or loss on the net monetary position, included in the net income. Moreover, their financial statements are converted into euros using the closing exchange rate of the relevant period.
IAS 29: impact on reported data � million except % | Q2 2025 | H1 2025 | ||
Sales | -5.9 | -37.3 | ||
Sales growth (%) | - | - | ||
Recurring Operating Income | -15 | |||
Recurring Net Income � Group share | -18 |
Breakdown by quarter of H1 2025 sales after application of IAS 29
H1 2025 sales correspond to the addition of:
- Q2 2025 reported sales;
- Q1 2025 sales resulting from the application of IAS 29 until June 30, 2025, to sales of entities in hyperinflationary countries (application of the inflation rate until June 30, 2025, and translation into euros using the June 30, 2025, closing rate) and provided in the table below for information (unaudited data)
� million | Q1 20251 | Q2 2025 | H1 2025 |
Europe | 2,389 | 2,505 | 4,894 |
North America | 1,633 | 1,546 | 3,179 |
China, North Asia & Oceania | 936 | 1,080 | 2,017 |
Latin America | 697 | 714 | 1,411 |
Asia, Middle East & Africa | 1,169 | 1,067 | 2,236 |
Total | 6,824 | 6,913 | 13,737 |
1Results from the application of IAS 29 until June 30, 2025, to Q1 sales of entities of hyperinflation countries.
Definitions of geographical zones
Europe refers to European countries.
North America refers to the United States and Canada.
China, North Asia & Oceania refers to China, Japan, Australia and New Zealand.
Latin America refers to Mexico, Brazil, Argentina and Uruguay.
Asia, Middle East & Africa (AMEA) refers to Asia, Middle East including Turkey, Africa and CIS (zone previously called “Rest of the World�).
Financial indicators not defined in IFRS
Due to rounding, the sum of values presented may differ from totals as reported. Such differences are not material.
Like-for-like changes in sales reflect Danone's organic performance and essentially exclude the impact of:
- changes in consolidation scope, with indicators related to a given fiscal year calculated on the basis of the previous year's scope;
- changes in applicable accounting principles;
- changes in exchange rates, with both previous-year and current-year indicators calculated using the same exchange rate (the exchange rate used is a projected annual rate determined by Danone for the current year and applied to both previous and current years).
Since January 1, 2023, all countries with hyperinflationary economies are taken into account in like-for-like changes as follows: sales growth in excess of around
Bridge from like-for-like data to reported data
(� million except %) | 2024 sales | Like-for-like change | Impact of changes in scope of consolidation | Impact of changes in exchange rates & others incl. IAS29 | Contribution of hyperinflation | Reported change | 2025 sales |
Q2 | 6,938 | + | - | + | - | 6,913 | |
H1 | 13,757 | + | - | - | + | - | 13,737 |
Margin from operations is defined as the Gross margin over Sales ratio, where Gross margin corresponds to the difference between Sales, Industrial costs (excluding reengineering initiatives) and Logistics / Transportation costs.
Recurring operating income is defined as ٲԴDzԱ’s operating income excluding Other operating income and expenses. Other operating income and expenses comprise items that, because of their significant or unusual nature, cannot be viewed as inherent to ٲԴDzԱ’s recurring activity and have limited predictive value, thus distorting the assessment of its recurring operating performance and its evolution. These mainly include:
- capital gains and losses on disposals of businesses and fully consolidated companies;
- under IAS 36, impairment charges on intangible assets with indefinite useful lives;
- costs related to strategic restructuring operations or transformation plans;
- costs related to major external growth transactions;
- costs related to crises and major disputes;
- in connection with IFRS 3 and IFRS 10, (i) acquisition costs related to acquisitions of companies resulting in control, (ii) revaluation gains or losses accounted for following a loss of control, and (iii) changes in earn-outs subsequent to acquisitions resulting in control.
Recurring operating margin is defined as the Recurring operating income over Sales ratio.
Other non-recurring financial income and expense corresponds to financial income and expense items that, in view of their significant or unusual nature, cannot be considered as inherent to ٲԴDzԱ’s recurring financial management. These notably include changes in the value of non-consolidated interests and profits or losses on the net monetary position.
Non-recurring income tax corresponds to income tax on non-recurring items as well as tax income and expense items that, in view of their significant or unusual nature, cannot be considered as inherent to ٲԴDzԱ’s recurring performance.
Recurring effective tax rate measures the effective tax rate of ٲԴDzԱ’s recurring performance and is computed as the ratio of income tax related to recurring items over recurring net income before tax.
Non-recurring share of profit (loss) of equity-accounted companies includes items that, because of their significant or unusual nature, cannot be viewed as inherent to the companies' recurring activity and thereby distort the assessment of their recurring performance and trends in that performance. These items mainly relate to:
- capital gains and losses on disposals of Investments in equity-accounted companies;
- impairment of investments in equity-accounted companies;
- non-recurring items, as defined by Danone, included in the share of profit (loss) of equity-accounted companies.
Recurring net income (or Recurring net income � Group Share) corresponds to the Group share of the consolidated Recurring net income. The Recurring net income excludes items that, because of their significant or unusual nature, cannot be viewed as inherent to ٲԴDzԱ’s recurring activity and have limited predictive value, thus distorting the assessment of its recurring performance and its evolution. Such non-recurring income and expenses correspond to Other operating income and expenses, Other non-recurring financial income and expenses, Non-recurring income tax, and Non-recurring share of profit (loss) of equity-accounted companies. These items, excluded from Net income, represent Non-recurring net income.
Recurring EPS (or Recurring net income � Group Share, per share after dilution) is defined as the ratio of Recurring net income adjusted for hybrid financing over Diluted number of shares. In compliance with IFRS, income used to calculate EPS is adjusted for the coupon related to the hybrid financing accrued for the period and presented net of tax.
H1 2024 | H1 2025 | ||||||||
Recurring | Total | Recurring | Total | ||||||
Net income-Group share (� million) | 1,162 | 1,219 | 1,231 | 1,040 | |||||
Coupon related to hybrid financing net of tax (� million) | (2) | (2) | (2) | (2) | |||||
Number of shares | |||||||||
� Before dilution | 642,417,472 | 642,417,472 | 642,916,473 | 642,916,473 | |||||
� After dilution | 643,422,265 | 643,422,265 | 644,414,852 | 644,414,852 | |||||
EPS (�) | |||||||||
� Before dilution | 1.81 | 1.90 | 1.91 | 1.62 | |||||
� After dilution | 1.80 | 1.89 | 1.91 | 1.61 |
Free cash flow represents cash flows provided or used by operating activities less capital expenditure net of disposals and, in connection with IFRS 3, excluding (i) acquisition costs related to acquisitions of companies resulting in control, and (ii) earn-outs related to acquisitions of companies resulting in control and paid subsequently to acquisition date.
(� million) | H1 2024 | H1 2025 |
Cash flows provided by operating activities | 1,504 | 1,519 |
Capital expenditure | (319) | (373) |
Disposal of property, plant and equipment and acquisition costs related to acquisitions of companies resulting in control1 | 63 | 26 |
Free cash flow | 1,248 | 1,172 |
1 Represents acquisition costs related to acquisitions of companies resulting in control that were paid during the period
Net financial debt represents the net debt portion bearing interest. It corresponds to current and non-current financial debt (i) excluding Liabilities related to put options granted to non-controlling interests and earn-outs on acquisitions resulting in control and (ii) net of Cash and cash equivalents (including Short term investments) and Derivatives � assets managing net debt.
(� million) | December 31, 2024 | June 30, 2025 |
Non-current financial debt | 10,175 | 10,793 |
Current financial debt | 3,799 | 3,549 |
Short-term investments | (4,685) | (4,396) |
Cash | (1,475) | (1,619) |
Bank Overdraft | 828 | 861 |
Derivatives � non-current assets1 | (3) | (95) |
Derivatives � current-assets1 | (37) | (18) |
Net debt | 8,601 | 9,076 |
| - | - |
| (317) | (367) |
Net financial debt | 8,285 | 8,709 |
1 Managing net debt only
o o O o o
FORWARD-LOOKING STATEMENTS
This press release contains certain forward-looking statements concerning Danone that are subject to risks and uncertainties. In some cases, you can identify these forward-looking statements by forward-looking words, such as “estimate�, “expect�, “anticipate�, “project�, “plan�, “intend�, “objective�, “believe�, “forecast�, “guidance�, “foresee�, “likely�, “may�, “should�, “goal�, “target�, “might�, “will�, “could�, “predict�, “continue�, “convinced� and “confident,� the negative or plural of these words and other comparable terminology, or by using future dates. Forward looking statements in this document include, but are not limited to, predictions of future activities, operations, direction, performance and results of Danone.
These forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. For a detailed description of these risks and uncertainties, please refer to the “Risk Factors� section of ٲԴDzԱ’s Universal Registration Document (the current version of which is available at ).
Subject to regulatory requirements, Danone does not undertake to publicly update or revise any of these forward-looking statements. This document does not constitute an offer to sell, or a solicitation of an offer to buy Danone securities.
The presentation to analysts and investors will be broadcast live today from 8:00 a.m. (Paris time)
on ٲԴDzԱ’s website ().
Related slides will also be available on the website in the Investors section.
APPENDIX � Sales by geographical zone and by category (in � million)
Q1 | Q2 | H1 | ||||||||||||
2024 | 2025 | 2024 | 2025 | 2024 | 2025 | |||||||||
BY GEOGRAPHICAL ZONE | ||||||||||||||
Europe | 2,336 | 2,389 | 2,447 | 2,505 | 4,783 | 4,894 | ||||||||
North America | 1,737 | 1,633 | 1,595 | 1,546 | 3,331 | 3,179 | ||||||||
China, North Asia & Oceania | 840 | 936 | 1,001 | 1,080 | 1,841 | 2,017 | ||||||||
Latin America | 727 | 715 | 810 | 714 | 1,556 | 1,411 | ||||||||
Asia, Middle East & Africa | 1,150 | 1,170 | 1,084 | 1,067 | 2,246 | 2,236 | ||||||||
BY CATEGORY | ||||||||||||||
EDP | 3,474 | 3,381 | 3,298 | 3,261 | 6,785 | 6,632 | ||||||||
Specialized Nutrition | 2,183 | 2,306 | 2,213 | 2,307 | 4,414 | 4,606 | ||||||||
Waters | 1,132 | 1,156 | 1,426 | 1,345 | 2,557 | 2,500 | ||||||||
TOTAL | 6,789 | 6,844 | 6,938 | 6,913 | 13,757 | 13,737 |
Q1 2025 | Q2 2025 | H1 2025 | ||||||||||
Reported change | LFL change | Reported change | LFL change | Reported change | LFL change | |||||||
BY GEOGRAPHICAL ZONE | ||||||||||||
Europe | + | + | + | + | + | + | ||||||
North America | - | + | - | + | - | + | ||||||
China, North Asia & Oceania | + | + | + | + | + | + | ||||||
Latin America | - | + | - | + | - | + | ||||||
Asia, Middle East & Africa | + | + | - | + | - | + | ||||||
BY CATEGORY | ||||||||||||
EDP | - | + | - | + | - | + | ||||||
Specialized Nutrition | + | + | + | + | + | + | ||||||
Waters | + | + | - | - | - | + | ||||||
TOTAL | + | + | - | + | - | + |
All references in this document to Like-for-like (LFL) changes, Recurring operating income and margin, Margin from operations, Recurring net income, Recurring income tax rate, Recurring EPS, Free cash flow and Net financial debt, correspond to alternative performance measures not defined by IFRS. Their definitions, as well as their reconciliation with financial statements, are listed on pages 6 to 9.
Attachment
